Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Foundayo is the brand name for orforglipron, a prescription oral GLP-1 receptor agonist. It is used with a reduced-calorie diet and increased physical activity for long-term weight management in eligible adults. It comes as a tablet taken once daily.
read more about foundayo ...Foundayo helps adults with obesity reduce excess body weight and maintain weight reduction. It is also approved for adults with overweight who have at least one weight-related medical condition. It is not approved as a stand-alone treatment for type 2 diabetes.
Orforglipron activates GLP-1 receptors involved in appetite and food intake. This can help a person feel full and eat less. The dose is increased gradually based on treatment response and tolerability.
Take one tablet by mouth each day, with or without food. Swallow it whole without breaking, crushing, or chewing it. If you miss seven or more consecutive days, contact the prescriber about how to restart.
Nausea, constipation, diarrhea, and vomiting are common side effects. Seek medical advice promptly for persistent severe abdominal pain, which can be a sign of pancreatitis. Foundayo should not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
No. Foundayo is a tablet taken by mouth once daily.
No. It can be taken with or without food.
Its current U.S. approval is for long-term weight management in eligible adults. Having type 2 diabetes does not change that approved indication.
Oral contraceptive pills might not work as well when starting Foundayo or increasing its dose. Ask the prescriber about a non-oral method or an added barrier method for 30 days after each change.
FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program. Date Accessed October 6, 2026.
FOUNDAYO (orforglipron) tablets: Prescribing Information. Eli Lilly and Company. https://pi.lilly.com/us/foundayo-uspi.pdf. Date Accessed October 6, 2026.
Foundayo (orforglipron): Once-Daily Weight Management Pill. Eli Lilly and Company. https://foundayo.lilly.com/. Date Accessed October 6, 2026.
Orforglipron. MedlinePlus. https://medlineplus.gov/druginfo/meds/a626059.html. Date Accessed October 6, 2026.
Orforglipron (oral route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/orforglipron-oral-route/description/drg-80010478. Date Accessed October 6, 2026.